Sector News

Pfizer axing neuroscience jobs, but seeks new VC fund

January 9, 2018
Life sciences

Big Pharma Pfizer, on the eve of J.P. Morgan, the biggest biopharma dating event on the year, will cut around 300 jobs and a number of earlier stage projects from its neuroscience pipeline.

The move will see it back out of work in Alzheimer’s and Parkinson’s disease, two notoriously difficult areas for the industry, especially the former, which has not seen any real R&D advance in 15 years.

In a statement on Friday, Pfizer said it will be redirecting funds “to those areas where we have strong scientific leadership and that will allow us to provide the greatest impact for patients,” adding that its total spending on R&D will not change, which amounted to around $8 billion last year.

The ax will fall predominately in Cambridge and Andover, Massachusetts, and in Groton, Connecticut, with about 100 expected at each site.

Those projects up for the chop are preclinical, early and midstage clinical programs primarily focused on Alzheimer’s and Parkinson’s, but Pfizer could outlicense these, or cofund them, through venture investments.

It has a host of meds in these areas, including a phase 2 dopamine 1 activator for Parkinson’s, as well as four phase 1 Alzheimer’s drugs that include PF-05251749 and PF-06648671, a γ-secretase modulator.

This comes after many other Big Pharmas, and smaller biotechs, have failed to move the needle on Alzheimer’s disease drugs in R&D, making ROI on these types of projects precisely zero.

The changes will not hit work on its pain treatments Lyrica and tanezumab, or research into drugs for rare neurological diseases, the Big Pharma stressed.

But the company did say it will set up a neuroscience venture fund “to support continued efforts to advance the field,” although details were not shared. More should come of this later in the year, it adds, and will be focused on external projects.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach